Correction to Lancet Neurol 2024; 23: 1119–32

Abstract

Montalban X, Vermersch P, Arnold DL, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol 2024; 23: 1119–32—In this Article, the fourth column of table 2 for row “Adjusted mean number of lesions per scan” should have been 0·31 (0·26 to 0·37), the second sentence of the eighth paragraph in Results should read “Most patients (999 [88%] of 1131) exceeded the target exposure of 400 ng/mL × h”, and the appendix has been corrected. Belgin Petek Balcı should have been included in the EvolutionRMS2 investigator list. These corrections have been made to the online version as of March 18, 2026.